Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) saw a significant drop in short interest in the month of October. As of October 30th, there was short interest totaling 3,236,659 shares, a drop of 46.9% from the October 15th total of 6,094,189 shares. Based on an average daily volume of 1,127,185 shares, the short-interest ratio is presently 2.9 days. Currently, 5.9% of the shares of the stock are sold short.
Protara Therapeutics Stock Down 2.5%
Protara Therapeutics stock opened at $2.32 on Wednesday. The stock’s fifty day simple moving average is $2.83 and its 200-day simple moving average is $4.35. Protara Therapeutics has a twelve month low of $2.09 and a twelve month high of $7.82.
Protara Therapeutics (NASDAQ:TARA – Get Free Report) last released its quarterly earnings data on Friday, November 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.02. On average, analysts predict that Protara Therapeutics will post -1.37 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on the stock. Wall Street Zen raised shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Protara Therapeutics in a research report on Thursday, October 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $26.25.
Read Our Latest Analysis on TARA
Protara Therapeutics Company Profile
Protara Therapeutics is a clinical-stage biotechnology company developing treatments for cancer and rare diseases. Its programs are investigational and are not approved for general use. The company’s lead program, TARA-002, is a cell-based immunotherapy being studied for non-muscle invasive bladder cancer and lymphatic malformations. Protara is also developing intravenous choline chloride for people with intestinal failure-associated liver disease. Protara was formed in 2019 through a merger involving ArTara Therapeutics.
Featured Stories
- Five stocks we like better than Protara Therapeutics
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
